Personalis and Tempus AI are adding colorectal cancer as a new indication to their existing commercialization agreement.

Tempus AI TEM is entering a phase of strong operating momentum, backed by significant acceleration in both revenues and gross profit. This trend became particularly clear in the company’s last two ...

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- Several experts are seeing that value of AI's total overhaul ...

Tempus AI is leading the charge in precision oncology with its data-driven, AI-enabled platform, while Butterfly Network is changing point-of-care imaging with its portable ultrasound devices and ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter, with year-over-year revenue up 75.4% and quarterly gross profit nearly doubling, the Chicago-based health ...

Tempus AI (NASDAQ: TEM), a fast-rising player in clinical AI and health data infrastructure, will report its Q1 2025 earnings after the market closes today.

Tempus would receive $200 million in data licensing and model development fees. The latest Pathos funding round has about $117 million left to sell, the filing notes.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the TD Cowen 45th Annual Health Care Conference on ...